Antibody conjugation has been a major step in the development of new therapies for different types of treatments. In this process, drugs are coupled with antibodies so as to enhance their delivery to the desired site of action. It is a treatment technique that has come to be popularly known as targeted therapy. The entire complex is known as an antibody drug complex or simply, ADC. ADCs are now commonly used in the treatment of cancer and other conditions.
There are a number of advantages that can be attributed to the use of conjugate antibodies. Perhaps the most important is the fact that there is some degree of synergism between these two components of the complex. Side effects associated with the use of chemotherapeutic agents are a very common occurrence. This is mainly due to the inability of the chemotherapeutic agents to differentiate the cancerous cells from the normal ones. With the use of the ADCs, however, the distinguishing ability is greatly enhanced.
The science that is involved in the process is rather complex but we will try to understand the main steps that take place. The main requirements for the process are a chemotherapeutic agent (cell toxin) and monoclonal antibodies. These antibodies have specific targets in the body. Each type of tumour secretes unique substances known as tumour markers and these can be easily targeted.
Once the complex gets into the blood, there is interaction between the monoclonal antibodies and the proteins on the cancer cells which act as antigens. A linkage is formed between the antibodies and the antigens. A signal is transmitted to the cell nucleus and the complex is subsequently absorbed into the cell. The drug is then released and acts on the cell to cause destruction.
The link formed between the ADC components must be stable. There are several types of links that exist. These are classified into two broad classes: cleavable and non-cleavable. The cleavable links include the disulfides and the peptides and the non-cleavable are the thioethers. Both types of linkages have been shown to be safe to users through clinical trials. ADCs comprising cleavable links usually have some enzymes.
There are a number of other applications other than drug delivery. Radionuclide agents have been delivered to target cells in very much the same way. This technique is popularly known as radioimmunotherapy and carries numerous advantages over conventional radiotherapy. For instance, the high specificity for targets has resulted in way fewer side effects than was the case in the past. It is also an effective method for treatment of metastatic disease.
Several disadvantages attributable to the use of ADCs have been identified. For example, there is a need to test for tumour markers before developing the effective antibodies. This is both a technically-demanding and expensive exercise. Another advantage is the fact that a considerable degree of dilution takes place on the pharmacological agent in the blood stream and this may reduce the potency.
Antibody conjugation has greatly helped in the development of new therapies and their delivery. Research efforts to fine tune this technique are ongoing. The main aims are to reduce the associated disadvantages and to enhance drug potency at the site of action.
There are a number of advantages that can be attributed to the use of conjugate antibodies. Perhaps the most important is the fact that there is some degree of synergism between these two components of the complex. Side effects associated with the use of chemotherapeutic agents are a very common occurrence. This is mainly due to the inability of the chemotherapeutic agents to differentiate the cancerous cells from the normal ones. With the use of the ADCs, however, the distinguishing ability is greatly enhanced.
The science that is involved in the process is rather complex but we will try to understand the main steps that take place. The main requirements for the process are a chemotherapeutic agent (cell toxin) and monoclonal antibodies. These antibodies have specific targets in the body. Each type of tumour secretes unique substances known as tumour markers and these can be easily targeted.
Once the complex gets into the blood, there is interaction between the monoclonal antibodies and the proteins on the cancer cells which act as antigens. A linkage is formed between the antibodies and the antigens. A signal is transmitted to the cell nucleus and the complex is subsequently absorbed into the cell. The drug is then released and acts on the cell to cause destruction.
The link formed between the ADC components must be stable. There are several types of links that exist. These are classified into two broad classes: cleavable and non-cleavable. The cleavable links include the disulfides and the peptides and the non-cleavable are the thioethers. Both types of linkages have been shown to be safe to users through clinical trials. ADCs comprising cleavable links usually have some enzymes.
There are a number of other applications other than drug delivery. Radionuclide agents have been delivered to target cells in very much the same way. This technique is popularly known as radioimmunotherapy and carries numerous advantages over conventional radiotherapy. For instance, the high specificity for targets has resulted in way fewer side effects than was the case in the past. It is also an effective method for treatment of metastatic disease.
Several disadvantages attributable to the use of ADCs have been identified. For example, there is a need to test for tumour markers before developing the effective antibodies. This is both a technically-demanding and expensive exercise. Another advantage is the fact that a considerable degree of dilution takes place on the pharmacological agent in the blood stream and this may reduce the potency.
Antibody conjugation has greatly helped in the development of new therapies and their delivery. Research efforts to fine tune this technique are ongoing. The main aims are to reduce the associated disadvantages and to enhance drug potency at the site of action.
About the Author:
If you want to find antibody conjugation, pay a visit to the web pages online here at www.columbiabiosciences.com today. You can see details at http://www.columbiabiosciences.com now.
No comments:
Post a Comment